20181220-Phase-1-TG4001-EN
Category: 2018
Transgene Announces Financial Calendar for 2019
20181217 Financial calendar 2019 EN
Transgene Announces Upcoming Investor Meetings
20181205-PR-Investors-Meeting-agenda-T1-2019.pdf
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation Collaboration between Transgene – Laboratoire de Recherches Biochirurgicales, Université Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France – Université Paris Diderot, Sorbonne Paris Cité, Paris, France – Hôpital Saint-Louis, Assistance Publique-Hôpitaux… Continue reading Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
20181112 PR TG0150 Phase 1 data combi AASLD EN
Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
Jean-Baptiste Marchand et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – BioInvent International A.B, Sweden
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Claire Fournier, et al. AASLD, The Liver Meeting 2018, November 2018 – Abstract available on the AASLD website Download the poster here Poster Presentation
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
Karola Rittner, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
20181107 SITC Poster EN